Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-986278 Thorough QT/QTc Study in Healthy Participants
NCT07422298Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Feb 2026
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of admilparant in idiopathic pulmonary fibrosis (IPF) (4 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Change from baseline Fridericia's corrected QT interval and Placebo-corrected change from baseline QTcF. Started Feb 2026; status: completed.
02
Drugs
admilparant
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT07422298.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07422298.